Hydroxychloroquine-induced inverse psoriasis
نویسندگان
چکیده
منابع مشابه
Exacerbation of Psoriasis due to Hydroxychloroquine
[email protected] Abstract Systemic Anti-malarial Drugs (SADs) are commonly used to treat autoimmune diseases and are generally considered a benign medication. SAD-induced psoriasis has been reported in the literature, but evidence is conflicting regarding the strength of the association of SAD and psoriasis exacerbations. We present a case of hydroxychloroquine-induced psoriasis exacerbat...
متن کاملHydroxychloroquine Induced Retinopathy: A Case Series
Background and Purpose: Occular toxicity is one of the most important complications of Hydroxychloroquine. Not any type of treatment has so far been found and recommended for this disorder. The purpose of this study was to report some characteristics of patients with Hydroxychloroquine Induced Retinopathy. Materials and Methods: From 107 patients with rheumatoid arthritis (...
متن کاملHydroxychloroquine-induced pruritus.
Sir, Hydroxychloroquine is a derivative of chloroquine and is frequently used in dermatological practice in the management of a number of conditions including photosensitivity disorders. There are a number of recorded side-e¡ects of this therapy. Pruritus is a well recognized side-e¡ect of chloroquine treatment of malaria in Africans and has also, rarely, been reported in Caucasians. To our kno...
متن کاملInverse Psoriasis with Autoimmune Hepatitis
820 Ann Dermatol Received August 30, 2016, Revised November 3, 2016, Accepted for publication November 25, 2016 Corresponding author: Kui Young Park, Department of Dermatology, Chung-Ang University Hospital, 102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea. Tel: 82-2-6299-1525, Fax: 82-2-823-1049, E-mail: [email protected] This is an Open Access article distributed under the terms of the Creative...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ Case Reports
سال: 2019
ISSN: 1757-790X
DOI: 10.1136/bcr-2018-224619